Spruce Biosciences Company Insiders
| SPRB Stock | USD 60.06 0.16 0.27% |
Spruce Biosciences' insiders are aggressively selling. The analysis of the overall insider sentiment regarding Spruce Biosciences Common suggests that all insiders are panicking. Spruce Biosciences employs about 9 people. The company is managed by 11 executives with a total tenure of roughly 21 years, averaging almost 1.0 years of service per executive, having 0.82 employees per reported executive.
Insider Sentiment
Mostly Selling
Selling | Buying |
Latest Trades
| 2025-10-06 | Parkman Healthcare Partners Ll | Disposed 257 @ 19.14 | View |
Following insider trading sentiment in Spruce Biosciences can help investors add context around confidence, timing, and operating risk while the public narrative is still evolving. The signal is still regulated and disclosed under securities law, which is why the public filing record matters more than rumor or interpretation alone.
Spruce Biosciences has a market cap of 64.29 M, ROE of -109.25%. See World Market Map for portfolio-level analysis. This suggests a position in Spruce Biosciences Common within the allocation view. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.Spruce Biosciences' Workforce Through the Years
A workforce review of Spruce Biosciences matters because hiring and staffing trends often say something about growth plans, cost discipline, and management expectations. Current projections suggest a workforce around about 17 employees by April 2026, which should be reviewed alongside revenue and margin trends.Macro event markers
Spruce Biosciences Management Team Effectiveness
The company has return on total asset (ROA) of -36.41 % which indicates that every $100 deployed in assets resulted in a loss of $36.41. This is significantly below industry benchmarks. Similarly, it shows a return on stockholder's equity (ROE) of -109.25 %, meaning that it produced losses on money invested by shareholders.As of the beginning of March, Financial models indicate Common Stock Shares Outstanding may fall to approximately 581.1 K. In addition to that, Financial models indicate Net Loss may fall to approximately -43.6 M
Stock Ownership Analysis
About 68.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 84.32. Spruce Biosciences Common had not issued any dividends in recent years. The company completed a 1:75 stock split on 7th of August 2025.Stock Institutional Investors
Institutional ownership matters in Spruce Biosciences Common because pension funds, mutual funds, banks, and advisers can materially influence liquidity, governance, and price discovery. Used correctly, institutional data helps investors understand who may be setting the marginal price and how resilient that holder base could be under stress.
| Shares | Ikarian Capital, Llc | 2025-09-30 | 13.3 K | Resolute Capital Asset Partners Llc | 2025-12-31 | 4 K | Skyview Investment Advisors, Llc | 2025-12-31 | 3 K | Bnp Paribas Arbitrage, Sa | 2025-12-31 | 2 K | Lion Point Capital, Lp | 2025-09-30 | 1000 | Ubs Group Ag | 2025-09-30 | 132 | Morgan Stanley - Brokerage Accounts | 2025-09-30 | 98.0 | Caldwell Sutter Capital Inc | 2025-09-30 | 13.0 | Bank Of America Corp | 2025-09-30 | 3.0 | The Carlyle Group Inc | 2025-09-30 | 2.9 M | Wellington Management Company Llp | 2025-12-31 | 58.9 K |
Insider Trading Activities
Insider trading disclosures for Spruce Biosciences Common offer a structured way to watch how people closest to the business are behaving while expectations change across the market. Current market capitalization is about 64.29 Million. Used properly, these records are better for context than for blind buy-or-sell signals.
Outstanding Bonds
Reviewing Spruce Biosciences Common bond obligations helps investors understand how much of the business is financed with fixed-income capital rather than purely with equity. This is why bond analysis is not just a credit exercise; it also informs equity holders about solvency, optionality, and future capital-allocation pressure.
| SPIRIT AEROSYSTEMS INC Corp BondUS85205TAG58 | View | |
| SPIRIT AEROSYSTEMS INC Corp BondUS85205TAK60 | View | |
| SPRINT NEXTEL P Corp BondUS85208NAE04 | View | |
| Sprint 6875 percent Corp BondUS852060AD48 | View | |
| Sprint 875 percent Corp BondUS852060AT99 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Corporate Filings
10K | 9th of March 2026 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
13A | 24th of February 2026 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
F3 | 18th of February 2026 An amendment to the original Schedule 13D filing | ViewVerify |
13A | 17th of February 2026 An amended filing to the original Schedule 13G | ViewVerify |
13A | 10th of February 2026 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
8K | 5th of February 2026 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 21st of January 2026 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 8th of January 2026 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Spruce Stock Holders Distribution
Institutional ownership analysis for Spruce Biosciences Common matters because banks, hedge funds, pension plans, and other professional investors can influence price and liquidity more forcefully than smaller holders. This matters because getting in early on a sponsorship cycle may help, but getting caught near a large-holder exit can have the opposite effect.
Spruce Biosciences Market Cap and Value
Spruce Biosciences Workforce Comparison
Spruce Biosciences Common is rated below average in number of employees among leading competitors. The total workforce of Health Care industry is at this time estimated at about 253. Spruce Biosciences holds roughly 9.0 in number of employees claiming about 4% of equities under Health Care sector.
Spruce Biosciences Insider Trading History
Insider trading disclosures for Spruce Biosciences Common offer a structured way to watch how people closest to the business are behaving while expectations change across the market. Current market capitalization is about 64.29 Million. Used properly, these records are better for context than for blind buy-or-sell signals.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2025-12-01 | 0.9348 | 43 | 46 | 93,841 | 52,257 |
| 2024-12-01 | 0.5 | 9 | 18 | 954,000 | 1,294,390 |
| 2024-03-01 | 0.6 | 3 | 5 | 619,200 | 4,172,336 |
| 2023-12-01 | 1.375 | 11 | 8 | 1,714,016 | 340,459 |
| 2023-06-01 | 4.0 | 12 | 3 | 387,862 | 100,936 |
| 2023-03-01 | 2.5 | 5 | 2 | 5,004,700 | 52,793 |
| 2022-06-01 | 7.0 | 14 | 2 | 538,571 | 50,468 |
| 2022-03-01 | 1.5 | 3 | 2 | 1,070,000 | 250,000 |
| 2021-06-01 | 2.4 | 12 | 5 | 104,688 | 503,758 |
| 2020-12-01 | 0.6552 | 19 | 29 | 20,048,947 | 124,792,389 |
Spruce Biosciences Notable Stakeholders
Stakeholders matter for Spruce Biosciences because not every influential participant is a shareholder acting with the same objective or time horizon. This becomes more informative when investors want to understand not just ownership, but influence, incentives, and strategic pressure points.
| Michael Grey | Executive Chairman | Profile | |
| Kirk MD | Interim Director | Profile | |
| CPA CPA | Pres CFO | Profile | |
| MD III | Chief Officer | Profile | |
| Libbie MBA | Chief Officer | Profile | |
| P Ramtin | Senior Operations | Profile | |
| Heidi MPH | Senior Quality | Profile | |
| Daven PharmD | Senior Quality | Profile | |
| Corwin Hooks | Chief Officer | Profile | |
| MSc BPHARM | Senior Operations | Profile | |
| MPH MD | CEO Director | Profile |
Management Information & Data Sources
Spruce Biosciences is a micro-cap company in Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care. Executive review focuses on insiders, senior management, and employee signals. Insider participation may help assess long-term alignment, especially during strategy transitions. CEO is MPH MD with 9 employees and 11 reported executives.
Macroaxis compiles Spruce Biosciences Common metrics from periodic company reporting and market reference feeds and applies consistent transformation rules before display. Analyst inputs may be included when coverage is available. Not all fields update in real time. Insider and management fields are mapped from published filings and company disclosures.
This content is curated and reviewed by:
Gabriel Shpitalnik - Member of Macroaxis Editorial BoardWorkforce Efficiency and Productivity
Investors reviewing Spruce Biosciences Common can use workforce efficiency as another lens on execution, especially when comparing similar businesses in the same industry. A disciplined workforce review can reveal whether execution quality is improving beneath the top-line numbers.
Spruce Biosciences Manpower Efficiency
Return on Spruce Biosciences Manpower
| Revenue Per Employee | 77.4K | |
| Revenue Per Executive | 63.4K | |
| Net Loss Per Employee | 4.3M | |
| Net Loss Per Executive | 3.5M | |
| Working Capital Per Employee | 3.2M | |
| Working Capital Per Executive | 2.6M |
Popular Tools for Spruce Stock analysis
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |